SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (17372)3/13/1998 7:32:00 AM
From: Mudcat  Read Replies (3) | Respond to of 32384
 
Good Morning Henry:

Can you explain why Lgnd is trying to use Panretin & Targretin in combination with drugs such as Tamoxiflin(?spelling), Evista etc. when it appears from studies that Ligands drugs can produce the same or better results on their own. My guess is that it has to do with the high cost to develop a sales and distribution force. Can you comment..



To: Henry Niman who wrote (17372)3/13/1998 1:24:00 PM
From: Andreas Helke  Read Replies (1) | Respond to of 32384
 
I wonder if Ligand keeps enough of their pipeline for themselves to grow to a real huge company in the future. Lets say 20 to 100 times the current market cap.

I am somewhat disappointed that the respective pharma partner gets the majority of the earnings of the outlicenced products and indications. But of course I know that this is inevitable and many people think that Ligand still spends too much for research and development.

Andreas


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News